Description
Molsun (Molnupiravir) 200 mg
Molsun is a brand name for molnupiravir, an oral antiviral medicine used for COVID-19 in selected patients. Regulatory and guideline sources describe molnupiravir as a medicine that reduces SARS-CoV-2 replication and is intended for use in non-severe COVID-19 when other options are not suitable or accessible.
Active Ingredient and Medicine Class
The verified active ingredient is molnupiravir. It is a direct-acting antiviral and a nucleoside analogue prodrug. After conversion in the body, it acts on the viral RNA-dependent RNA polymerase.
Established Medical Uses
Official sources identify molnupiravir for the treatment of mild-to-moderate COVID-19 in adults at increased risk of progression to severe disease, with use generally reserved for situations where other approved or authorised treatment options are not appropriate or available. WHO’s living guideline supports use only in selected non-severe, high-risk patients and recommends against routine use in lower-risk groups.
How It Works
Molnupiravir is converted in the body to an active form that is incorporated into viral RNA. This increases copying errors in the virus’s genetic material, which interferes with SARS-CoV-2 replication.
Important Safety Information
Important safety restrictions include avoidance in pregnancy, because of concern for fetal harm; WHO also advises against use in pregnant and breastfeeding women and in children. Regulatory sources also note that molnupiravir should not be used as a substitute for vaccination or other public-health measures. Clinically significant interaction concerns are fewer than with many other antivirals, but full medicine reconciliation remains important because patients with COVID-19 may be taking multiple treatments.
Possible Side Effects
Reported adverse effects have included diarrhoea, nausea, dizziness and headache. Serious or important theoretical concerns discussed by regulators and WHO include possible genotoxicity-related risk and unknown longer-term harms, although human safety data have not shown a clear increase in serious adverse reactions in the clinical trial literature reviewed to date.
Scientific Evidence
Human evidence suggests molnupiravir can reduce viral replication, but clinical benefit has been more mixed than early reports implied. A recent systematic review and meta-analysis found improved viral clearance but no clear reduction in hospitalisation or all-cause mortality in adults with non-severe COVID-19. Other reviews have reached broadly similar conclusions, supporting a limited role in selected patients rather than broad routine use.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, prescribing information, or assessment by a qualified health professional.
Medical Sources
- European Medicines Agency (EMA) — Lagevrio: EPAR summary
- U.S. Food and Drug Administration (FDA) — Fact Sheet for Healthcare Providers: Emergency Use Authorization for LAGEVRIO (molnupiravir) capsules
- WHO — Therapeutics and COVID-19: living guideline, August 2025
- George N Okoli, Nicole Askin, Rasheda Rabbani et al. — Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials — Drugs (2026)
